New virtual biopsy could lead to major improvements in care for heart transplant patients

The days of heart transplant survivors undergoing invasive biopsies could soon be over after a new MRI technique has proven to be safe and effective; reducing complications and hospital admissions.

Scientists at the Victor Chang Cardiac Research Institute and St Vincent's Hospital, Sydney, hope the new virtual biopsy designed to detect any signs of the heart being rejected will be adopted by clinicians the world over.

Approximately 3500 people worldwide receive heart transplants each year. Most patients experience some form of organ rejection and whilst survival rates are high, a small percentage will die in the first year after surgery.

Associate Professor Andrew Jabbour, of the Victor Chang Cardiac Research Institute, said the new development will lead to major improvements in care for many thousands of heart transplant patients worldwide.

It's essential that we can monitor these patients closely and with a high degree of accuracy; now we have a new tool that can do that without the need for a highly invasive procedure.

This new virtual biopsy takes less time, is non-invasive, more cost-effective, uses no radiation or contrast agents, and most importantly patients much prefer it."

Andrew Jabbour, Associate Professor, Victor Chang Cardiac Research Institute and Consultant Cardiologist at St Vincent's Hospital, Sydney

Most clinicians around the world currently test for rejection by performing a biopsy which helps determine the level and suitability of immunosuppressive treatments needed to treat and prevent further rejection.

This invasive procedure involves a tube being placed in the jugular vein to allow surgeons to insert a biopsy tool into the heart to remove multiple samples of heart tissue.

As well as being uncomfortable, it can also lead to rare but serious complications if the heart is perforated, or a valve is damaged. Patients usually undergo a biopsy around 12 times in the first year after transplantation.

The new MRI technique has been proven to be accurate in detecting rejection and works by analyzing heart edema levels which the team demonstrated are closely associated with inflammation of the heart.

Key results

  • Forty heart transplant patients from St Vincent's Hospital, Sydney were randomized into receiving either a traditional biopsy or the new MRI technique.
  • Results published in the journal Circulation revealed the new test was just as effective as detecting rejection.
  • Secondary findings of the study revealed that despite similarities in immunosuppression requirements, kidney function and mortality rates, there was a reduction in hospitalization and infection rates for those who underwent the MRI procedure vs a biopsy. Also, just six percent of patients having the new MRI technique needed a biopsy for clarification reasons. These secondary findings are earmarked to be reconfirmed in planned larger multi-center studies.

Fellow author and cardiologist Dr Chris Anthony, who helped conduct the study, said: "The technique is now frequently used at St Vincent's Hospital in Sydney, and I anticipate that more clinics across the world will adopt this novel technology."

Next steps

The team at the Institute and St Vincent's is now planning a larger multi-center trial to broaden the applicability of the findings and incorporate pediatric transplant recipients.

They are also developing new genetic testing to be used alongside the MRI which it is hoped will detect signs of rejection through identifying genetic signals of donor-specific inflammation in the bloodstream. The new technique will also be adapted to detect heart inflammation in the wider population, not just transplant recipients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study identifies potential target for treating diabetic cardiomyopathy